IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.363
EU - Europa 905
AS - Asia 825
SA - Sud America 126
AF - Africa 15
OC - Oceania 2
Totale 3.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.335
CN - Cina 422
IE - Irlanda 313
SG - Singapore 174
RU - Federazione Russa 146
HK - Hong Kong 133
DE - Germania 126
BR - Brasile 110
FI - Finlandia 101
IT - Italia 81
GB - Regno Unito 27
IN - India 25
JP - Giappone 24
SE - Svezia 23
CA - Canada 14
FR - Francia 13
PL - Polonia 13
AT - Austria 11
ES - Italia 11
VN - Vietnam 11
MX - Messico 10
ZA - Sudafrica 10
LT - Lituania 8
NL - Olanda 7
BD - Bangladesh 6
TR - Turchia 6
CZ - Repubblica Ceca 5
BE - Belgio 4
CO - Colombia 4
IQ - Iraq 4
AR - Argentina 3
AZ - Azerbaigian 3
BO - Bolivia 3
GR - Grecia 3
AM - Armenia 2
AU - Australia 2
BG - Bulgaria 2
CL - Cile 2
IR - Iran 2
KR - Corea 2
LU - Lussemburgo 2
MU - Mauritius 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
HN - Honduras 1
JM - Giamaica 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TH - Thailandia 1
TM - Turkmenistan 1
UA - Ucraina 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
Totale 3.236
Salva come PNG Salva come JPEG
Città #
Dublin 311
Chandler 208
Dallas 182
Ashburn 135
Hong Kong 132
Beijing 131
Singapore 89
Helsinki 75
Nanjing 54
Los Angeles 53
Boardman 48
Munich 45
Shanghai 36
Princeton 35
Lawrence 34
New York 33
Medford 31
Wilmington 26
Pavia 25
Tokyo 23
Nanchang 21
Moscow 20
Jacksonville 19
Redondo Beach 18
Buffalo 16
Changsha 16
Shenyang 15
Hebei 14
Turku 14
Milan 13
Nuremberg 13
Piscataway 13
Tianjin 13
Chicago 12
São Paulo 12
Denver 11
Warsaw 11
Jiaxing 10
Falkenstein 9
Johannesburg 9
San Francisco 9
Chennai 8
London 8
Pune 8
Seattle 8
Stockholm 8
Frankfurt am Main 7
Hangzhou 7
Ho Chi Minh City 7
Norwalk 7
Orem 7
Vienna 7
Ankara 6
Santa Clara 6
Tamm 6
The Dalles 6
Woodbridge 6
Brooklyn 5
Fairfield 5
Houston 5
Hyderabad 5
Mexico City 5
Montreal 5
Poplar 5
Redwood City 5
Amsterdam 4
Atlanta 4
Brasília 4
Brussels 4
Cagliari 4
Catania 4
Phoenix 4
Rio de Janeiro 4
Toronto 4
Washington 4
Athens 3
Baku 3
Bexley 3
Boston 3
Brno 3
Charleston 3
Jinan 3
La Paz 3
Manchester 3
Mülheim 3
Newark 3
Pouso Alegre 3
San Jose 3
Vilnius 3
Vistarino 3
Belo Horizonte 2
Bogotá 2
Bollate 2
Casalecchio di Reno 2
Charlotte 2
Columbus 2
Council Bluffs 2
Delhi 2
Dongdaemun-gu 2
Düsseldorf 2
Totale 2.251
Salva come PNG Salva come JPEG
Nome #
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 102
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 100
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 100
A patient with AL amyloidosis with negative free light chain results 98
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 92
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 89
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 87
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 86
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 84
Prognostication of survival and progression to dialysis in AA amyloidosis 83
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 82
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 81
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 80
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 79
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 76
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 74
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 72
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 71
A case of monoclonal gammopathy of renal significance 71
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 69
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 68
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 68
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 67
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 67
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 65
The lung in amyloidosis 65
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 65
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 64
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 64
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 63
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 63
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 61
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 60
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 57
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 51
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 51
Development and Validation of Staging Systems for AA Amyloidosis 49
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 49
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 48
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 48
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 46
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 42
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 40
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 39
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 38
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 38
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 38
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 31
null 30
null 29
Renal amyloidoses 26
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 17
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS 15
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 14
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study 8
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 7
null 6
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis 5
Totale 3.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.194
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202155 0 0 0 0 1 5 3 17 25 2 0 2
2021/2022154 2 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025864 27 57 9 28 10 75 79 35 210 50 107 177
2025/2026892 147 149 193 308 95 0 0 0 0 0 0 0
Totale 3.338